Stockreport

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Phase 1a Trial of STAR-0310 in Healthy Volunteers Expected to Initiate in Q1 2025 ---- Early Proof-of-Concept Results Expected in Q3 2025 -- BOSTON--(BUSINESS WIRE [Read more]